JOHNSON & JOHNSON

(JNJ)
  Report
Real-time Estimate Cboe BZX  -  05/17 03:00:58 pm EDT
178.27 USD   +0.11%
08:55aFDA Expands Authorization of Pfizer Covid Booster to Kids 5 to 11
DJ
08:54aCitigroup Adjusts Price Target on Johnson & Johnson to $205 From $210, Reiterates Buy Rating
MT
05/16Mariners put RHP Steckenrider on restricted list, add Elías
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Morgan Stanley Adjusts Johnson & Johnson's Price Target to $175 from $187, Keeps Equalweight Rating

01/24/2022 | 11:09am EDT


ę MT Newswires 2022
All news about JOHNSON & JOHNSON
08:55aFDA Expands Authorization of Pfizer Covid Booster to Kids 5 to 11
DJ
08:54aCitigroup Adjusts Price Target on Johnson & Johnson to $205 From $210, Reiterates Buy R..
MT
05/16Mariners put RHP Steckenrider on restricted list, add Elías
AQ
05/13Idaho announces $119 million opioid crisis settlement
AQ
05/13What We're Reading This Week
AQ
05/12Johnson & Johnson to Participate in Goldman Sachs 43rd Annual Global Healthcare Confere..
PR
05/12Africa's Covid-19 Vaccine Production Line in Jeopardy
AQ
05/11TRANSCRIPT : Johnson & Johnson Presents at Bank of America 2022 Healthcare Conference, May..
CI
05/11Johnson & Johnson Names Thibaut Mongon CEO Designate of Planned New Consumer Health Com..
MT
05/11Johnson & Johnson Appoints CEO For Future Spin-off Unit
MT
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Financials (USD)
Sales 2022 96 249 M - -
Net income 2022 23 016 M - -
Net cash 2022 8 885 M - -
P/E ratio 2022 20,0x
Yield 2022 2,50%
Capitalization 469 B 469 B -
EV / Sales 2022 4,78x
EV / Sales 2023 4,54x
Nbr of Employees 141 700
Free-Float 84,2%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Last Close Price 178,08 $
Average target price 187,12 $
Spread / Average Target 5,08%
EPS Revisions
Managers and Directors
Joaquin Duato Chief Executive Officer & Director
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Matthew Stuckley Senior Financial Analyst-Janssen Commercial Pharm
Alex Gorsky Executive Chairman
Peter Shen Global Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON4.10%468 600
PFIZER, INC.-14.19%284 304
ABBVIE INC.14.82%274 733
ELI LILLY AND COMPANY8.38%269 490
ROCHE HOLDING AG-14.96%260 807
MERCK & CO., INC.20.46%233 459